Meriofert Set

Follicle-Stimulating Hormone; Luteinising Hormone, the active ingredient in Meriofert Set, is a gonadotropin presented as a sterile injectable solution for intramuscular or subcutaneous use. It is employed to stimulate ovarian follicular development and ovulation in women with infertility related to anovulation or hypogonadotropic hypogonadism.

GNH USA supplies Meriofert Set as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meriofert Set, a gonadotropin used in reproductive medicine, addresses several infertility‑related conditions.

- Infertility due to anovulation: promotes follicular growth and induces ovulation. - Controlled ovarian stimulation for assisted reproductive technologies: enhances the number of mature oocytes retrieved. - Hypogonadotropic hypogonadism: replaces deficient endogenous FSH and LH to restore normal ovarian function.

Adverse reactions may occur with any gonadotropin therapy. Monitoring and prompt reporting are essential.

Common Side Effects: - Injection site pain or erythema: mild discomfort at the injection site. - Abdominal discomfort: transient bloating or mild cramping. - Headache: mild to moderate intensity. - Nausea: occasional upset stomach. - Breast tenderness: mild swelling or soreness. - Mild ovarian hyperstimulation: limited follicular response.

Serious or Rare Side Effects: - Severe ovarian hyperstimulation syndrome: rapid weight gain, ascites, or respiratory distress. - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Allergic reactions: rash, itching, or anaphylaxis. - Multiple pregnancy: twins or higher order gestations. - Ectopic pregnancy: implantation outside the uterine cavity. - Severe abdominal pain: possible ovarian torsion or rupture.

Use Meriofert Set under specialist supervision with appropriate monitoring.

- Assess baseline ovarian reserve: perform ultrasound and hormone profiling before initiation. - Monitor estradiol levels: adjust dosage to avoid excessive stimulation. - Evaluate for contraindications: avoid in active malignancy or uncontrolled thyroid disease. - Counsel on signs of OHSS: educate patients to seek immediate care if symptoms arise. - Review concomitant medications: consider interactions that may amplify ovarian response. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions can modify the efficacy or safety of Meriofert Set.

Major Interactions (Avoid): - Concurrent use of other gonadotropins: may markedly increase risk of ovarian hyperstimulation syndrome. - High‑dose estrogen therapy: can blunt the intended ovarian response.

Moderate Interactions (Monitor Closely): - GnRH antagonists or agonists: may require dosage adjustments. - Anticoagulants: monitor for bleeding if invasive procedures are planned. - Thyroid hormone replacement: ensure euthyroid status to optimise response. - Corticosteroids: may affect follicular development, requiring close observation.